NASDAQ:VBLT

Vascular Biogenics Stock Forecast, Price & News

$2.20

-0.07 (-3.08 %)

(As of 06/22/2021 12:41 PM ET)

Add

Compare

Today's Range

$2.20

▼

$2.20

50-Day Range

$1.69

▼

$2.67

52-Week Range

$1.01

▼

$3.17

Volume100 shs

Average Volume898,723 shs

Market Capitalization$106.01 million

P/E RatioN/A

Dividend YieldN/A

Beta0.94

30 days | 90 days | 365 days | Advanced Chart

Receive VBLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Zacks: Brokerages Expect Vascular Biogenics Ltd. (NASDAQ:VBLT) Will Post Quarterly Sales of $370,000.00
June 19, 2021 | americanbankingnews.com

Brokerages Anticipate Vascular Biogenics Ltd. (NASDAQ:VBLT) to Post -$0.10 Earnings Per Share
June 17, 2021 | americanbankingnews.com

-$0.10 EPS Expected for Vascular Biogenics Ltd. (NASDAQ:VBLT) This Quarter
June 17, 2021 | americanbankingnews.com

Vascular Biogenics, Ltd. Investors: Company Investigated by the Portnoy Law Firm
June 17, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Biogenics Ltd. - VBLT
June 16, 2021 | finance.yahoo.com

VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
June 15, 2021 | finance.yahoo.com

Vascular Biogenics (NASDAQ:VBLT) Earns "Buy" Rating from Chardan Capital
June 3, 2021 | americanbankingnews.com

Roth Capital Increases Vascular Biogenics (NASDAQ:VBLT) Price Target to $7.00
June 3, 2021 | americanbankingnews.com

VBL Therapeutics Announces Addition of Progression Free Survival as a Second Primary Endpoint in OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer
June 3, 2021 | finance.yahoo.com

$370,000.00 in Sales Expected for Vascular Biogenics Ltd. (NASDAQ:VBLT) This Quarter
June 1, 2021 | americanbankingnews.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBLT
Previous SymbolNASDAQ:VBLX
CUSIPN/A
CIK1603207
Webwww.vblrx.com
Phone972-8993-5000
Employees38
Year FoundedN/A

Sales & Book Value

Annual Sales$920,000.00
Price / Sales115.23
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.64 per share
Price / Book3.44

Profitability

EPS (Most Recent Fiscal Year)($0.55)
Net Income$-24,230,000.00
Net Margins-3,394.74%
Return on Equity-68.79%
Return on Assets-53.15%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares48,187,000
Market Cap$106.01 million
Next Earnings Date8/12/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.18 out of 5 stars

Medical Sector

983rd out of 2,105 stocks

Pharmaceutical Preparations Industry

478th out of 832 stocks

3.5 Analyst's Opinion

Consensus Rating
Vascular Biogenics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.75, Vascular Biogenics has a forecasted upside of 153.3% from its current price of $2.27.
Amount of Analyst Coverage
Vascular Biogenics has only been the subject of 3 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
Vascular Biogenics has received 277 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Vascular Biogenics has received 302 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Vascular Biogenics has received 52.16% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Vascular Biogenics and other stocks. Vote “Outperform” if you believe VBLT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VBLT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Vascular Biogenics does not currently pay a dividend.
Dividend Growth
Vascular Biogenics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vascular Biogenics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 5.58% of the stock of Vascular Biogenics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Vascular Biogenics are expected to decrease in the coming year, from ($0.44) to ($0.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vascular Biogenics is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vascular Biogenics is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vascular Biogenics has a P/B Ratio of 3.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Vascular Biogenics (NASDAQ:VBLT) Frequently Asked Questions

Is Vascular Biogenics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vascular Biogenics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vascular Biogenics stock.
View analyst ratings for Vascular Biogenics or view top-rated stocks.

What stocks does MarketBeat like better than Vascular Biogenics?

Wall Street analysts have given Vascular Biogenics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vascular Biogenics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vascular Biogenics' next earnings date?

Vascular Biogenics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Vascular Biogenics.

How were Vascular Biogenics' earnings last quarter?

Vascular Biogenics Ltd. (NASDAQ:VBLT) issued its quarterly earnings results on Monday, May, 10th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.20 million. Vascular Biogenics had a negative net margin of 3,394.74% and a negative trailing twelve-month return on equity of 68.79%.
View Vascular Biogenics' earnings history.

How has Vascular Biogenics' stock price been impacted by COVID-19 (Coronavirus)?

Vascular Biogenics' stock was trading at $1.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VBLT shares have increased by 86.1% and is now trading at $2.27.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for VBLT?

4 brokers have issued 12 month price targets for Vascular Biogenics' shares. Their forecasts range from $4.00 to $7.00. On average, they anticipate Vascular Biogenics' share price to reach $5.75 in the next year. This suggests a possible upside of 153.3% from the stock's current price.
View analysts' price targets for Vascular Biogenics or view top-rated stocks among Wall Street analysts.

Who are Vascular Biogenics' key executives?

Vascular Biogenics' management team includes the following people:

Prof. Dror Harats, CEO & Director (Age 64)
Mr. Amos Ron, CFO & Company Sec. (Age 66)
Dr. Erez Feige, VP of Bus. Operations (Age 47)
Dr. Eyal Breitbart, VP of Research & Operations (Age 54)
Dr. Naamit Sher, VP of Drug Devel. & Regulatory Affairs (Age 67)
Advocate Ayelet Horn, Gen. Counsel (Age 50)
Deborah Scott, Managing Director of Financial Communications
Dr. Yael Cohen, Medical Director (Age 58)

Who are some of Vascular Biogenics' key competitors?

Some companies that are related to Vascular Biogenics include Oncorus (ONCR), Spero Therapeutics (SPRO), Neoleukin Therapeutics (NLTX), Amryt Pharma (AMYT), Kindred Biosciences (KIN), ANI Pharmaceuticals (ANIP), Werewolf Therapeutics (HOWL), Homology Medicines (FIXX), Oramed Pharmaceuticals (ORMP), KemPharm (KMPH), VistaGen Therapeutics (VTGN), Puma Biotechnology (PBYI), Foghorn Therapeutics (FHTX), Verona Pharma (VRNA) and Cue Biopharma (CUE).
View all of VBLT's competitors.

What other stocks do shareholders of Vascular Biogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN).

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Who are Vascular Biogenics' major shareholders?

Vascular Biogenics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Ikarian Capital LLC (1.66%), Morgan Stanley (1.50%), Squarepoint Ops LLC (0.24%), Renaissance Technologies LLC (0.16%), PVG Asset Management Corp (0.06%) and Steel Peak Wealth Management LLC (0.05%).

Which major investors are selling Vascular Biogenics stock?

VBLT stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Morgan Stanley.

Which major investors are buying Vascular Biogenics stock?

VBLT stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Squarepoint Ops LLC, PVG Asset Management Corp, Steel Peak Wealth Management LLC, HBK Sorce Advisory LLC, and Vident Investment Advisory LLC.

How do I buy shares of Vascular Biogenics?

Shares of VBLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vascular Biogenics' stock price today?

One share of VBLT stock can currently be purchased for approximately $2.27.

How much money does Vascular Biogenics make?

Vascular Biogenics has a market capitalization of $109.38 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-24,230,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Vascular Biogenics have?

Vascular Biogenics employs 38 workers across the globe.

What is Vascular Biogenics' official website?

The official website for Vascular Biogenics is www.vblrx.com.

Where are Vascular Biogenics' headquarters?

Vascular Biogenics is headquartered at 8 HASATAT STREET, MODI IN L3, 7178106.

How can I contact Vascular Biogenics?

Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The biopharmaceutical company can be reached via phone at 972-8993-5000 or via email at [email protected]

This page was last updated on 6/22/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here